Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Matritech (NASDAQ - NMPS) -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (559)	2/13/1998 2:40:00 PM
From: Mark C. Hurley	Read Replies (2) \| Respond to of 849

Hi Bill, I am new to this site, but not new to Matritech. I read through these folders and there was pretty good information in here. I agree with John that the colorectal cancer product that is in Phase I of FDA clinical trials (4 months now) is the big money maker for this stock. But noone should cross off the NMP22 test kit. It is still the best prostate cancer screening test around, and it's the foundation for a group of marketable products. The only problem is that so far the marketing for Matritech stinks. Another product may change that. I read posts from a while ago with concern over Bayer backing out on Matritech's colorectal test. Quite frankly, I hope they do. The product is good enough to attract other pharmaceutical companies. Don't forget that Bayer has made a large contribution in money to Matritech. If they back out, Matritech keeps the money and the product. That's a win-win situation. It may be easier to sell the colorectal product with the NMP22 test kit already on the market. It may even help it NMP22 sales.